Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Mylan N.V.(NASDAQ:MYL)’s Generic Version Of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA)’s Copaxone Approved

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 04:16pm CET

A generic version of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA)’s Copaxone which has been developed by Mylan N.V.(NASDAQ:MYL) has been approved by the U.S. Food and Drug Administration. Copaxone is a blockbuster drug that is used in the treatment of multiple sclerosis.

The approval of the copaxone generic was a surprise to both Teva and Mylan since they had not been expecting it to happen so soon. This came a day after the FDA announced that measures would be introduced with a view to speeding up the approval of generics of complex drugs such as copaxone so that they can get to the market faster and assist in addressing the increasing cost of drugs.

Blockbuster drug

Copaxone is not only the leading therapy for multiple sclerosis in the world but is also the best-selling drug ever developed by Teva. Last year it generated revenues amounting to over $4 billion for the pharmaceutical giant headquartered in Tel Aviv, Israel.

According to Teva, the launch of the generic version of Copaxone was being done prior to the resolution of a couple of patent appeals. This implies that Mylan would end up paying significant damages in the event that Teva prevailed.

Two varying doses of the generic were approved by the FDA and this include the 40 mg dose and the 20mg dose. In this year’s second quarter, over 85% of the Copaxone prescriptions were made for the 40 mg dose.

Loss for Teva

According to analysts the approval amounted to a win for Mylan and a loss for Teva and projected that this would be reflected in both this year’s and next year’s earnings. Mylan’s first generic-version application for Copaxone was filed in 2009.

“Bottom line, this is incrementally positive for Mylan while for Teva both a negative surprise and a cash flow hit to 2018,” wrote Randall Stanicky, an RBC analyst, in a client note.

Two months ago U.S. Congress launched an investigation on drug pricing and Teva was among the pharmaceutical companies contacted over the cost of its multiple sclerosis drug. In 2017 the annual cost for the 20 mg dose of Copaxone is over $90,000 despite the fact that it was unveiled in 1996 and back then it used to cost approximately $8,000.

On Wednesday shares of Mylan N.V. rose by 16.20% to close the day at $37.80.

The post Mylan N.V.(NASDAQ:MYL)’s Generic Version Of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA)’s Copaxone Approved appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
09:36p EXCLUSIVE : Teva to fire 500 managers in Israel
04:00p TEVA PHARMACEUTICAL INDUSTRIES : Announces Exclusive Launch of Generic Viagra® T..
03:29p TEVA PHARMACEUTICAL INDUSTRIES : Announces Exclusive Launch of Generic Viagra® T..
12/10 TEVA PHARMACEUTICAL INDUSTRIES : mulls 10,000 layoffs - report
12/08 TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
12/08 TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
12/08DJTEVA PHARMACEUTICAL INDUSTRIES : May Cut Up to 10,000 Jobs -Bloomberg
12/07 TEVA PHARMACEUTICAL INDUSTRIES : Researchers Submit Patent Application, "Treatme..
12/04 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : Today’s Research Reports on Trending Tick..
11/30 TEVA PHARMACEUTICAL INDUSTRIES : Report Summarizes Copaxone Therapy Study Findin..
More news
News from SeekingAlpha
03:42p FDA accepts Lilly's marketing application for migraine med galcanezumab
05:25a TEVA : Is This What A Bloodbath Looks Like?
02:38a BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Sage's Depression Results, Pfizer's Viagr..
12/08 Teva may cut as many as 10K jobs; shares up 6%
12/05 TEVA PHARMACEUTICAL : A Holiday Season Sale
Financials ($)
Sales 2017 22 633 M
EBIT 2017 6 276 M
Net income 2017 -
Debt 2017 34 419 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,23x
EV / Sales 2018 2,13x
Capitalization 16 129 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 24,5 $
Spread / Average Target 54%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Michael R. Hayden Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-62.32%15 034
JOHNSON & JOHNSON21.23%377 698
NOVARTIS11.34%218 728
PFIZER9.48%213 036
ROCHE HOLDING LTD.6.19%208 877
MERCK AND COMPANY-7.68%151 559